PACSIN2 regulates mercaptopurine cytotoxicity and cellular biomechanics through Rac1 modulation in intestinal epithelial cells
Alessia Norbedo, Giulia Zudeh, Donatella Fiducioso, Beatrice Senigagliesi, Pietro Parisse, Loredana Casalis, Giuliana Decorti, Marianna Lucafò, Gabriele Stocco · 2026
Read PACSIN2 regulates mercaptopurine cytotoxicity and cellular biomechanics through Rac1 modulation in intestinal epithelial cells by Alessia Norbedo, Giulia Zudeh, Donatella Fiducioso, Beatrice Senigagliesi, Pietro Parisse, Loredana Casalis, Giuliana Decorti, Marianna Lucafò, Gabriele Stocco (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13575966.txt.
Description
Alessia Norbedo and co-authors link a gene variant to chemotherapy side effects in gut cells in this 2026 paper. Mercaptopurine treats childhood leukemia and bowel disease, but some patients suffer gut toxicity. A variant near the PACSIN2 gene lowers its level in gut tissue. PACSIN2 partners with Rac1, a protein that shapes the cell skeleton.
In gut cells, cutting PACSIN2 raised Rac1 and made cells more sensitive to the drug. Adding more PACSIN2 did the opposite, shielding the cells. Loss of the protein also softened cells and scrambled their skeleton. The drug itself lowered stiffness and Rac1 further. The authors offer a molecular reason for the clinical link between the variant and gut harm.
Catalog record
| CREATOR | Alessia Norbedo, Giulia Zudeh, Donatella Fiducioso, Beatrice Senigagliesi, Pietro Parisse, Loredana Casalis, Giuliana Decorti, Marianna Lucafò, Gabriele Stocco |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |